Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance

David H. Aggen,Carissa E. Chu,Jonathan E. Rosenberg

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 3|浏览18

暂无评分

摘要

Clinical data with enfortumab vedotin (EV) suggest that most bladder cancers overexpress NECTIN-4. A recent article shows that NECTIN-4 membranous expression changes with progression to metastatic disease and that low NECTIN-4 expression in metastatic biopsies is potentially associated with EV resistance. These data argue for incorporation of NECTIN-4 expression into future biomarker strategies.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要